Companies /Healthcare

Johnson & Johnson

NYSE: JNJ Drug Manufacturers - General
$275.23
▼ $3.20 (−1.15%) today
Markets closed · 7:25pm ET

Q4 2025 Earnings

Reported Jan 21, 2026, 7:46am ET · SEC source
$2.46
Miss −0.19%
EPS · est. $2.46
$24.6B
Beat +1.69%
Revenue · est. $24.2B
+13.2%
Beating market
JNJ vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
0+2%+4%Jan 21Jan 22report 7:46am ETearnings+2.1%+3.0%
0+2%+4%Jan 21Jan 22earnings+2.1%+3.0%
JNJ +3.0%S&P 500 +2.1%
0+2%+4%Jan 21Jan 22report 7:46am ETearnings+2.5%+3.0%
0+2%+4%Jan 21Jan 22earnings+2.5%+3.0%
JNJ +3.0%NASDAQ +2.5%
0+3%+6%Jan 20Jan 29report 7:46am ETearnings+3.0%+7.6%
0+3%+6%Jan 20Jan 29earnings+3.0%+7.6%
JNJ +7.6%S&P 500 +3.0%
0+3%+6%Jan 20Jan 29report 7:46am ETearnings+4.5%+7.6%
0+3%+6%Jan 20Jan 29earnings+4.5%+7.6%
JNJ +7.6%NASDAQ +4.5%
−0.09%
Day of report
+0.22%
Next session
+4.45%
One week
+12.77%
30 days

S&P 500 over the same 30 days: −0.44%.

Did JNJ Beat Earnings? Q4 2025 Results

Johnson & Johnson closed out 2025 on a high note, reporting Q4 revenue of $24.56 billion — up 9.1% year-over-year and ahead of the $24.13 billion Wall Street had expected — while adjusted EPS of $2.46 matched consensus exactly, representing a 20.6% jump from the prior-year period. The standout driver was the Innovative Medicine segment, where oncology powerhouse DARZALEX surged 26.6% to $3.90 billion and TREMFYA soared 67.6% to $1.59 billion, more than offsetting a steep 47.7% decline in STELARA amid biosimilar pressure. MedTech contributed meaningfully as well, with cardiovascular sales climbing 11.5% to $2.30 billion — a gain that comes as J&J makes inroads in electrophysiology, adding competitive pressure on rivals in the pulsed field ablation space. Full-year sales reached $94.19 billion, and management is guiding for roughly $100.50 billion in 2026 revenue alongside adjusted EPS of $11.53 — projections that reflect confidence in a <a href="https://247wallst.com/investing/2026/01/10/the-glp-1-blockbuster-maker-widens-its-lead-as-the-diversified-healthcare-giant-posts-steady-growth/">diversified growth trajectory</a> anchored by oncology momentum and a planned Orthopaedics separation.

Key Takeaways
  • DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE driving Oncology growth
  • TREMFYA and SIMPONI/SIMPONI ARIA driving Immunology growth despite STELARA biosimilar erosion
  • SPRAVATO and CAPLYTA driving Neuroscience growth
  • Electrophysiology products and Abiomed driving MedTech Cardiovascular growth
  • Wound closure products driving General Surgery growth
  • Shockwave acquisition contributing to MedTech growth

“2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history”

Johnson & Johnson CEO, on the earnings call

Forward Guidance & Outlook

For full-year 2026, Johnson & Johnson guides for estimated reported sales of approximately $100.5 billion at the midpoint, representing 6.7% growth, and adjusted EPS of $11.53 at midpoint, representing 6.9% growth. The guidance uses an illustrative Euro average rate of $1.17 for January 2026.

JNJ YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$7.0B$14.0B$21.0B$22.5B$24.6BRevenue$15.4B$16.6BGross Profit$3.4B$5.1BNet Income
$0$7.0B$14.0B$21.0BRevenueGross ProfitNet Income

JNJ Revenue by Segment

Innovative Medicine$15.8B+10.0%
MedTech$8.8B+7.5%
DARZALEX$3.9B+26.6%
Surgery$2.6B+5.5%
Surgery (MedTech)
Orthopaedics$2.4B+5.3%
Cardiovascular (MedTech)$2.3B+11.5%
STELARA$1.2B−47.7%

JNJ Revenue by Geography

United States$14.2B+7.5%
Rest of World$10.4B+11.3%
Europe
Asia Pacific, Africa
Western Hemisphere excluding U.S.

Figures from SEC filings and company reports. Not investment advice.